Mysimba is a medicine used to lose weight. Also known as Contrave in USA, this product contains the active ingredients naltrexone and bupropion; what they’ll do is to act in the brain's reward system to influence your eating behavior. You will have less appetite and will be able to control your cravings for sugary and fatty foods. Mysimba is indicated for people who are obese or struggling with overweight. If you are presently with a body mass index (BMI) of 27 kg/m2 or higher, you are at risk of developing diabetes and have high blood pressure. Do not overlook obesity as you may increase the risk of many diseases like cardiovascular diseases, diabetes and high blood pressure. If you use Mysimba, you can significantly reduce the risk of diseases by losing weight.
Mysimba is approved for use in patients with an initial body mass index of 30 or higher. Nevertheless, if your body mass index is between 27 and 30 or there are other weight-related conditions (hypertension, type 2 diabetes or high lipid levels), you can use it as well for higher benefits. Pay close attention to your doctor’s instructions, if after 16 weeks you have not dropped at least 5 % of your initial body weight, your doctor may remove you from Mysimba. The treatment can also be stopped if you show an elevated blood pressure, or for any other reason your doctor finds relevant.
|Treatment||Dosage||Quantity||Per Pill||Price||Buy now|
An online doctor consultation means filling out a medical questionnaire. A registered EU doctor assesses your medical questionnaire and analize whether Mysimba is suitable and safe for you to buy. After approval, a prescription is issued and send to the registered EU pharmacy. You will receive your discretely shipped Mysimba pills within 3 business days.
Mysimba aka Contrave is approved for use in patients with an initial body mass index of 30 or higher. However, it can also be given to persons with a body mass index between 27 and 30 if there are other weight-related conditions, such as regulated high blood pressure (hypertension), type 2 diabetes or high lipid levels (fat). Mysimba may be discontinued by your doctor after 16 weeks if you have not dropped at least 5 percent of your initial body weight. Your doctor may also recommend stopping treatment if there is concern about elevated blood pressure, or if there are concerns regarding the safety of this medicine.
The attempt to market anti-obesity drugs continues, last week Ema the European Medicines Agency announced that it has given its approval to the marketing of the Mysimba, produced by the American laboratory Orexigen Therapeutics.
Mysimba, a combination of two active ingredients, naltrexone, used for the treatment of opiate and alcohol addiction and bupropion prescribed as an antidepressant and also used to combat addiction to smoking is a noradrenaline and dopamine reuptake inhibitor.
The two active substances according to accredited sources aim to control two key areas of the brain, the first is the arcuate nucleus of the hypothalamus, the area of the brain that plays a role in controlling food intake and energy expenditure, while the second is the mesolimbic pathway of the dopaminergic system that controls the rewarding aspects of food and food-related stimuli.
Ema emphasizes that it will be available only on medical prescription and is reserved for obese or overweight adults with one or more risk factors such as hypertension, high cholesterol, diabetes, risk factors common to all obese people over the long term. It should be taken with a low-calorie diet program and physical activity.
A drug that aims to capture the compliance of the assisted person with obesity that will allow greater control of food and adherence to the hypocaloric diet program and physical activity. Because a lot of people surrender to the first difficulties, especially if they are not supported by an incentive program for weight loss reasons.
The most interesting aspect is that if after a period of 16 weeks if the patient has not lost at least 5% of the initial weight, the drug can no longer be prescribed.
Some researchers are worried about the side effects of the drug, the Ema agency indicates the possibility of gastrointestinal disorders or those related to the central nervous system and in the long term instead there is talk of cardiovascular problems even if the studies submitted for authorization, if corrected, seem to be reassuring on serious cardiovascular diseases.
On the American site instead we talk about the drug Contrave, which should be the original version of the drug marketed in the American market, composed of naltrexone and bupropion, where the side effects of the Contrave are written , I must say of not minor importance, it goes from simple diarrhea dry mouth but also behavioral disorders such as suicidal thoughts, panic attacks, sleep disturbances, irritability, aggressiveness, and nervousness, which need more than a deepening, at the moment what is known is that Mysimba should be the European version of Contrave, contains the same active ingredients and are from the same company.
I remember that until now the anti-obesity drugs were all failures, withdrawn from the market because they were considered dangerous for health or because they gave rise to side effects that do not justify their use but also due to the complexity of the pathology of obesity.
Personally, I am against taking drugs, but I recognize that there are people who cannot control the appetite impulse, perhaps it is more to these that the drug can be prescribed, Obesity is a multi-factorial pathology, therefore it is necessary not only to assess BMI and the risk of cardiovascular disease and diabetes, we need to assess what factors have generated the disease.
Curious also the name Mysimba, my while Simba in the Swahili language, one of the official languages of the African Union, means lion, to call a drug my lion, is funny, even if maybe it would be a name more suitable for another kind of drugs.
The drug is a drug is not a toy but certainly, the name attracts sympathy, a sort of the last frontier of the new pharmaceutical marketing.
Obesity, is a multi-factorial disease, must not be forgotten genetic predisposition, therapy should be individualized and dealt not only with drugs but with the help of a multidisciplinary team, so the drug should be taken under medical supervision, but the team must re-educate the assisted person to have a good relationship with food for a more balanced diet that can be managed with support from the team at the beginning but independent at a later time, this is the most difficult aspect.
Obesity is not just a medical problem or a health problem, it is a social problem in the sense that part of the responsibility can be directed to the Food Industry, with products increasingly rich in a mix of greases, sugars and salt, a communication that invites and stimulates us to eat more, at any time of day or night, there must also be a change in the industry and in the supply of food, combined with greater politics, grant me this term, which favors and stimulates the movement and physical activity, because pharmaceutical treatment alone may not be sufficient.